Showing 1211-1220 of 2820 results for "".
- Intravenously and Subcutaneously Infused Levodopa/Carbidopa for Advanced Parkinson Diseasehttps://practicalneurology.com/news/intravenously-and-subcutaneously-infused-levodopacarbidopa-for-advanced-parkinson-disease/2470016/Pharmacokinetic findings from a study (NCT00660673) of intravenous levodopa/carbidopa (LCIV) (DIZ101; Dizlin Pharmaceuticals, Gothenburg, Sweden) or subcutaneous l
- Blarcamesine Reduces Rett Syndrome Symptomshttps://practicalneurology.com/news/blarcamesine-reduces-rett-syndrome-symptoms/2469814/Blarcamesine (Anavex2-73; Anavex Life Sciences Corp, New York, NY), once daily oral liquid doses of up to 30mg, demonstrated statistically significant reductions in Rett syndrome symptoms with related changes in potential biomarkers, GABA and L-Alpha-aminoadipic acid (L-AAA), of disease pathology
- Over $500,000 Awarded for ALS and Mitochondrial Myopathies Researchhttps://practicalneurology.com/news/over-500000-awarded-for-als-and-mitochondrial-myopathies-research/2470938/The Muscular Dystrophy Association (MDA; Chicago, IL) has partnered with the French Muscular Dystrophy Association (AFM-Téléthon; Evry, France) to award a total of $510,000 in grant funding across 2 research projects. The grant funding is intended to accelerate the development of tr
- Barancik Prize Awarded to Dr. Ruth Ann Marrie at ACTRIMS 2023https://practicalneurology.com/news/barancik-prize-awarded-to-dr-ruth-ann-marrie-at-actrims-2023/2470120/The National Multiple Sclerosis Society announced that Ruth Ann Marrie, MD, P
- Fenfluramine May Usher in Higher Standards for Treatment of Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-may-usher-in-higher-standards-for-treatment-of-dravet-syndrome/2469642/In an editorial in Epilepsy and Behavior, Helen Cross, MD and Joseph Sullivan, MD suggest fenfluramine (Fintepla; Zogenix, Emeryville, CA) clinical trial results can raise the bar for efficacy of antiseizure medications (ASMs) for
- Peanut Consumption May Lower Risk of Strokehttps://practicalneurology.com/news/peanut-consumption-may-lower-risk-of-stroke/2469686/According to new research published in Stroke, people living in Japan who ate peanuts (on average 4-5 peanuts/day) had a lower risk of ischemic stroke or a cardiovascular disease event. Previous studies have l
- Award Recipients Recognized at the 2024 International Congress of Parkinson’s Disease and Movement Disordershttps://practicalneurology.com/news/award-recipients-recognized-at-the-2024-international-congress-of-parkinsons-disease-and-movement-disorders/2470598/The International Parkinson’s Disease and Movement Disorders Society (MDS) has announced recipients of the 2024 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The
- FDA Approves Mirabegron for Neurogenic Detrusor Overactivity in Pediatric Patientshttps://practicalneurology.com/news/fda-approves-mirabegron-for-neurogenic-detrusor-overactivity-in-pediatric-patients/2469543/The Food and Drug Administration approved a new indication for mirabegron extended-release tablets (Myrbetriq; Silver Spring, MD) and mirabegron for extended-release oral suspension (Myrbetriq Granules; Silver Spring, MD) to treat neurogenic detrusor overactivity (NDO) in children age 3 yea
- Experimental BTK Inhibitor Suppressed Inflammatory Disease Activity in Those with Relapsing MShttps://practicalneurology.com/news/long-term-treatment-with-fenebrutinib-suppressed-inflammatory-disease-activity-in-relapsing-ms/2473796/Fenebrutinib (Roche, Basel, Switzerland), an investigational oral, reversible noncovalent Bruton tyrosine kinase (BTK) inhibitor, demonstrated significant efficacy in suppressing inflammatory disease activity in people with relapsing multiple sclerosis (RMS) according to the results of the open-l
- FDA Grants Accelerated Approval to Gene Therapy for the Treatment of AADC Deficiencyhttps://practicalneurology.com/news/fda-grants-accelerated-approval-to-gene-therapy-for-the-treatment-of-aadc-deficiency/2470636/Kebilidi (eladocagene exuparvovec-tneq; PTC Therapeutics, Warren, NJ) has been granted Food and Drug Administration (FDA) approval under the Accelerated Approval pathway for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is an ad